The U.S. market is essential
Amgen is among the larger biotech and pharma companies by market capitalization worldwide. Biopharmaceuticals manufactured by Amgen are also among the leading biotech drugs worldwide. Enbrel, Prolia, and Otezla are the company’s flagship products, responsible for over one third of Amgen’s total revenue. Interestingly, Amgen generates over 70 percent of its revenues on the domestic U.S. market.Research and development
As is common in the biopharmaceutical industry, Amgen spends a significant proportion of its income on research and development. In 2022, Amgen spent nearly 17 percent of its total revenues on R&D purposes. More than one third of 4.4 billion U.S. dollars of R&D spending was for late-stage clinical programs, while the rest was for discovery research and for marketed products.
